May. 22 at 12:38 PM
$DRRX From Grok: A reasonable acquisition valuation for DURECT Corporation, considering Larsucosterol’s potential in AH, the AHFIRM trial results, and the market opportunity, is
$250–
$450 million. This range balances the strong clinical data (especially U.S. subgroup results), FDA designations, and blockbuster potential against clinical and financial risks. A strategic acquirer with a focus on hepatology or orphan drugs might lean toward the higher end, while a more conservative buyer might target the lower end.
